Bellicum Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Bellicum Pharmaceuticals's estimated annual revenue is currently $1.1M per year.
- Bellicum Pharmaceuticals received $Undisclosed in venture funding in April 2018.
- Bellicum Pharmaceuticals's estimated revenue per employee is $7,568
- Bellicum Pharmaceuticals's total funding is $301.8M.
- Bellicum Pharmaceuticals has 148 Employees.
- Bellicum Pharmaceuticals grew their employee count by -11% last year.
- Bellicum Pharmaceuticals currently has 1 job openings.
|David Spencer||Chief Scientific Officer|
|Joseph Senesac||VP Manufacturing/Viral Vector Development|
|Rick Fair||President & CEO|
|Scott Cullison||Vice President, Commercial Planning and Program Management|
|Kim Luu||Director Analytical|
|Eric Bourhis||Director, Business Development & Strategy|
|Steve Toler||Vice President, Pharmaceutical Development|
|Kurt Mickelson||Director - Clinical Supply Chain|
|Joanna Stanson||Director, Contract Manufacturing Relations|
|Aaron Foster||Vice President of Product Discovery|
What Is Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy. We are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Family Tree DNA||$5.7M||40||18%||N/A|
Bellicum Pharmaceuticals News
Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement. Pricing of $57.5 Million Public Offering of ...
Bellicum Pharmaceuticals (NASDAQ:BLCM) is offering to sell shares of its Series 1 preferred stock and warrants to purchase common shares in ...
Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan ...
Bellicum Pharmaceuticals Funding
|2012-03-09||$20.0M||B||AVG Ventures LP, Remeditex Ventures||Article|
Bellicum Pharmaceuticals Executive Hires
|2007-10-11||Amount: 3.75||Round: Undisclosed||Article|
|2012-04-13||David M. Spencer||Chief Scientific Officer||Article|
|2015-10-30||Alan K Smith||SVP Manufacturing||Article|
|2017-08-04||Gregory Naeve||Chief Business Officer||Article|
|2018-02-06||William Grossman||Chief Medical Officer||Article|
|2018-05-30||Shane Ward||General Counsel and Corporate Secretary||Article|